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Background 
- SCI current data and statistics 
• Prevalence and incidence worldwide 
• Prevalence and incidence in Romania 
• Average age at injury, male: female     
   ratio 
- Medical and social consequences of 
SCIs 
• Clinical classifications of SCIs 
• Medical complications/ co-morbidities 
- Current therapeutic means and their 
limitations in SCIs 
- Current context of Regenerative 
Medicine 
 
Integrative emphases regarding limits, detrimental 
pathways and related targets for neuroprotection/ 
recovery, in SCI 
- Morpho-functional, inner restrictions 
of the CNS/ spinal cord’s post injury self-
repair  
- Primary injuries in SCI 
- Secondary injuries - patho-
physiological events’ cascade - targets for 
neuroprotection 
- Final (irreversible) consequences of 
SCIs 
- Current trends in SCI (experimental) 
therapies 
 
Integrative emphases – clinical/ therapeutic 
connections 
- “Classical” drugs, with a long history of 
clinical use 
- New/ experimental drugs/ procedures 
Stem cells & tissue engineering - background 
- Medical and social potential 
- Brief history of stem cell research 
- Spontaneous regeneration phenomena 
in lower vertebrates 
- Definition of Regenerative Medicine 
- Definition and clinical use of tissue 
engineering 
- Stem cells: 
• Definition  
• Classifications 
• Main characteristics & properties 
• Embryonic stem cells 
• Adult stem cells 
 
Regenerative Medicine in SCI repair 
- Main issues/ problems 
• Ethical concerns 
• The availability of suitable stem cells 
• The inhibitory environment of the 
lesioned SC, especially in chronic SCI (glial 
scar, cyst formation) → grafts fail to survive 
• Immune reactions to allografts/ 
xenografts 
• Regeneration with aberrant 
reconnections → neuropathic pain, 
spasticity 
• Contamination of the stem cell lines 
with feeder cells, bacteria and/or 
transfection with feeder cells genic material 
• High proliferative capacity of ESC → 
cancer risc 
- The role of glial scar prevention 
therapy (Regeneration Promoting Therapy) 
•Cordaneurin  
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•CordaChron  
•Chondroitinase ABC  
- Current status of preclinical and 
clinical research of stem cells in SCI repair 
•clinical studies currently underway 
- Human embryonic stem cells (hESCs) 
- Fetal stem cells: 
•Fetal OEG (olfactory ensheathing glia) 
•Fetal Schwann cells 
•Umbilical cord blood cells 
- Adult stem cells: 
•Mesenchymal stem cells/ Marrow 
Stromal Cells (MSC) 
•Olfactory ensheathing glia (OEG) - 
including of differentiated ones transplants 
•Schwann cells - - including of 
differentiated ones transplants 
•Adult-derived neural progenitor cells 
NPCs 
- Stem cell research at the Teaching 
Emergency Hospital “Bagdasar-Arseni”, 
Bucharest, Romania 
- Tissue engineering in SCI repair 
•Polymeric scaffolds used for spinal 
cord regeneration - properties 
•“Smart” biomaterials - characterized by 
stereospecificity and self-assembling - 
nano-scale  self-assembling  bio-scaffolds 
•Recent conceptual & technological 
breaktroughs: implants built by 3D-
printing 
•RP (rapid printing) machine (for 
replacement organs and whole bodies) 
•“Direct writing” - printing implants by 
MAPLE-DW 
Conclusions 
Considering the complexity of SCI 
pathobiology, it is important to adopt 
multifactorial (combinatory) strategies, that 
may include: 
- (Stem) cell replacement  
- Long distance guidance of neural re-
growth and re-connection 
- Advanced scaffolding/ encapsulation 
(for cells replacement)/ tissue re-
construction 
- Local delivery of neuroprotective/ 
neurotrophic substances (e.g. scar 
formation inhibitors, growth factors, 
neurotrophins) 
- Surgical removal of glial scars, 
posttraumatic cysts 
- Integrated Physical therapy 
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